Stock Selection: Kimi's picks for 2026-09-11
Kimi picked AAPL, XLE, SWKS, ELV, QRVO for a 1-day horizon. Portfolio return vs SPY: +1.46%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | Kimi |
| Prompt version | stock-selection-v7 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-10 |
| Measured to | 2026-09-11 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +1.46% |
| Picks that beat SPY | 60% |
| Benchmark return | +0.85% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | AAPL | +1.75% | 72% | +0.89% | Yes |
| 2 | XLE | +0.32% | 70% | -0.53% | No |
| 3 | SWKS | +5.14% | 62% | +4.29% | Yes |
| 4 | ELV | +0.52% | 58% | -0.33% | No |
| 5 | QRVO | +3.82% | 55% | +2.97% | Yes |
The model's market view
The S&P 500 has declined for three straight sessions into the September 10 close as Brent crude surged above $100 (WTI near $104, +8% on the day) on escalating US-Iran conflict — US forces destroyed five Iranian tankers and Houthi allies struck Saudi energy facilities — while Treasury yields sit at 2023 highs. In this tape, leadership is concentrated in energy (best-performing sector, XLE +48% YTD) and in idiosyncratic catalyst names: Apple is riding post-'Surprise and Shine' event momentum after unveiling its first foldable iPhone and the iPhone 18 Pro line, and the Skyworks-Qorvo merger arb is repricing higher as China's SAMR review enters its final phase. Defensive healthcare is also attracting rotation. I favor equal-weight exposure to these four themes — Apple event momentum, energy via XLE, the SWKS/QRVO merger pair, and Elevance Health's defensive momentum — over the benchmark, while avoiding rate-sensitive tech semis (NVDA, INTC fell sharply on September 10) and fuel-cost-sensitive consumer and airline names.
Why each pick
AAPL
Thesis: Apple rallied +3.56% to $326.57 on September 10 with heavy volume (70M vs 54M average) following its September 9 'Surprise and Shine' keynote — new CEO John Ternus's first product launch — which unveiled the first foldable iPhone (iPhone Duo/Ultra, $2,000-$3,000) and iPhone 18 Pro models with the A20 Pro chip. Bank of America analysis shows AAPL has gained in the 60 days following iPhone reveal days 17 times since 2007, and post-event momentum typically extends over the following sessions as product details and pre-order commentary circulate. The foldable is a genuine new category with a multi-year upgrade-cycle narrative, and AAPL's mega-cap quality profile is attractive in a risk-off tape where the broad index is falling. Risks: the classic sell-the-news pullback after a hyped event; a lofty foldable price point could draw skeptical takes; broad-market weakness and rising yields could drag even strong names; China demand and tariff headlines remain an overhang.
XLE
Thesis: Crude oil spiked roughly 8% on September 10 to about $104/bbl, the highest since May, as the US-Iran war escalated — the US military destroyed five Iranian tankers, Iran reported strikes on US warships and tankers in the Persian Gulf, Houthi allies hit Saudi energy facilities, Saudi production fell ~1.9M bpd in August, and tanker rates hit record highs amid Strait of Hormuz disruption. Energy is by far the best-performing sector (XLE +48% YTD vs SPY roughly flat-to-negative) and the conflict shows no sign of abating, with analysts warning it could drag on for years. XLE pulled back -0.58% on September 10 despite the oil spike (intraday profit-taking after touching a 52-week high of $66.41), setting up a catch-up move on September 11 if crude holds its surge; top holdings XOM (19.9%) and CVX (15.2%) are cash-flow machines leveraged to sustained $100+ oil. Risks: a sudden de-escalation headline or ceasefire could trigger a sharp oil pullback; OPEC+ supply response; demand destruction from high prices; energy equities can diverge from crude on any given day.
SWKS
Thesis: SWKS surged +9.79% to $84.03 on September 10 on merger-arb repricing — CEO Phil Brace confirmed China's SAMR antitrust review of the Qorvo combination has advanced to phase three, the final stage, with management targeting a year-end close; over 90% of Qorvo's 2029 and 2031 notes were tendered in exchange offers (deadline extended to September 11), and the company lined up $2B of acquisition financing plus a $2B buyback. The stock is also an Apple RF-content supplier benefiting from the iPhone 18/foldable launch cycle, and Brace's fireside chat at the Goldman Sachs Communacopia conference on September 10 could generate fresh bullish headlines going into September 11. The move occurred on a day the SOX semiconductor index fell 2%, underscoring idiosyncratic strength. Risks: the merger is not guaranteed to close and any snag could unwind the arb premium quickly; BMO initiated coverage at Market Perform with a $70 target, below the current price; a Halper Sadeh shareholder-rights investigation adds headline risk; high beta to any broad tech selloff.
ELV
Thesis: Elevance Health jumped +5.41% to $416.54 on September 10, leading the S&P 500 gainers, with the strongest momentum in the managed-care group. The company reported Q2 2026 results ahead of expectations in July, raised 2026 adjusted EPS guidance to at least $27.00, and guided to a return to at least 12% adjusted EPS growth in 2027 — a credible turnaround narrative in a defensive sector that attracts rotation when oil-driven inflation and rising yields pressure the broader market. The stock is up ~33% over the past year, carries a forward P/E of only ~13.6x, and 15 of 22 analysts rate it Buy with a median target of $457 (+13.7%). Healthcare is a classic outperformer during geopolitical-risk-off sessions. Risks: the +5.4% single-day move may invite profit-taking on September 11; the Q3 dividend record date (September 10) has passed, removing an incremental buyer; medical-cost trend and Medicare margin execution remain watch items; a relief rally in risk assets would reduce the defensive bid.
QRVO
Thesis: Qorvo climbed +6.77% to $112.36 on September 10 alongside Skyworks on the same merger-arb repricing — the combined $22B RF leader is nearing the finish line with China's SAMR review in its final phase and a year-end close targeted; Qorvo shareholders are the acquisition target, so the stock is a cleaner expression of deal-completion odds plus any merger-spread compression. QRVO is also a key Apple RF supplier into the iPhone 18/foldable cycle, giving it a second idiosyncratic tailwind independent of the weak broader semiconductor tape (NVDA -2.4%, INTC -5.6% on September 10). Risks: highly correlated with SWKS, so the pair concentrates portfolio risk in a single deal; if regulators delay or block the merger, both names could gap down; no same-day company-specific catalyst beyond the shared merger story; semiconductor-sector weakness could eventually pull it lower despite the idiosyncratic story.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Claude Opus 5 | ACVA, ORCL, FEIM, CPRT, RH | +15.60% | 40% |
| Gemini 1.5 Pro | ORCL, XOM, CVX, ELV, CHTR | -0.14% | 20% |
| Muse Spark 1.1 | ORCL, ADBE, AAPL, NVDA, MSFT | -0.45% | 40% |
| GPT-5.6 Sol | ORCL, XLE, AAPL, CNQ, BIIB | -0.91% | 20% |
| Grok 4.5 | XLE, XOM, CVX, COP, AAPL | -0.18% | 20% |
| DeepSeek V3 | ORCL, RH, CPRT, XLE, BAC | -1.61% | 0% |
Written up on ForecastNest Insights: Stock Selection: Kimi's picks for 2026-09-11.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.